Invex Therapeutics (ASX:IXC) Total Equity : A$5.30 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Total Equity?

Invex Therapeutics's total equity for the quarter that ended in Dec. 2023 was A$5.30 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Invex Therapeutics Total Equity Historical Data

The historical data trend for Invex Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Total Equity Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Total Equity

24.40

32.08

28.48

21.23

5.69

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Equity	Get a 7-Day Free Trial					28.48	24.74	21.23	5.30	5.69

Invex Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Invex Therapeutics's Total Equity for the fiscal year that ended in Jun. 2024 is calculated as

Total Equity	=	Total Assets(Q: Jun. 2024 )	-	Total Liabilities(Q: Jun. 2024 )
	=	6.12	-	0.432
	=	5.69

Invex Therapeutics's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	6.28	-	0.985
	=	5.30

Invex Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.